Mutual of Omaha Bank Wealth Management bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,153 shares of the biopharmaceutical company’s stock, valued at approximately $823,000.

A number of other hedge funds have also modified their holdings of GILD. Keel Point LLC increased its holdings in shares of Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares in the last quarter. Paradigm Financial Advisors LLC increased its holdings in shares of Gilead Sciences by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 26 shares in the last quarter. West Oak Capital LLC increased its holdings in shares of Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares in the last quarter. First Heartland Consultants Inc. increased its holdings in shares of Gilead Sciences by 0.4% during the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 39 shares in the last quarter. Finally, Princeton Portfolio Strategies Group LLC increased its holdings in shares of Gilead Sciences by 0.4% during the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 41 shares in the last quarter. Institutional investors and hedge funds own 75.94% of the company’s stock.

Gilead Sciences, Inc. (GILD) opened at $72.71 on Tuesday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27. The firm has a market capitalization of $94,978.82, a price-to-earnings ratio of 8.28, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the previous year, the firm earned $2.75 earnings per share. The business’s revenue was down 13.2% on a year-over-year basis. equities analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.86%. Gilead Sciences’s dividend payout ratio is currently 23.69%.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.56, for a total value of $6,054,372.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last three months, insiders sold 494,999 shares of company stock worth $37,404,139. Insiders own 1.30% of the company’s stock.

GILD has been the subject of several recent research reports. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. Royal Bank of Canada initiated coverage on Gilead Sciences in a report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price objective for the company. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Robert W. Baird restated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Wells Fargo & Co restated a “market perform” rating and set a $81.00 price objective (up previously from $73.00) on shares of Gilead Sciences in a report on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $85.03.

COPYRIGHT VIOLATION NOTICE: “Mutual of Omaha Bank Wealth Management Takes $823,000 Position in Gilead Sciences, Inc. (GILD)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://theolympiareport.com/2017/12/26/mutual-of-omaha-bank-wealth-management-takes-823000-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.